Mantle Cell Lymphoma Mimicking Rectal Carcinoma
نویسندگان
چکیده
منابع مشابه
Mantle Cell Lymphoma Mimicking Rectal Carcinoma
Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma. After the (11;14) translocation was identified as its constant finding in 1992, MCL was recognized as a separate subgroup of non-Hodgkin lymphoma (NHL). In MCL, extranodal involvement may be observed in the bone marrow, the spleen, the liver, and the gastrointestinal system (GIS). Cases of MCL that present with a massive and so...
متن کاملRecurrent mantle cell lymphoma presenting as a solitary rectal mass.
stool for 2 months. He had been diagnosed as having mantle cell lymphoma of the spleen 8 years ago, and complete remission was achieved after chemotherapy. A computed tomography (CT) scan of the abdomen, taken to evaluate the intraabdominal lymph nodes, revealed a rectal mass with perilesional lymphadenopathy, A primary rectal cancer was suspected (●" Fig. 1, 2). Colonoscopy revealed an ulcerat...
متن کاملMantle Cell Lymphoma with Multiple Lymphomatous Polyposis Presenting With Intussusceptions
Mantle cell lymphoma is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node. The gastrointestinal tract is the predominant site of extranodal involvement in the form of multiple lymphomatous polyposis. Multiple lymphomatous polyposis due to mantle cell lymphoma presenting with intussusception is ...
متن کاملMantle Cell Lymphoma
American Society of Hematology in the first 2 years has also been reduced by 50% in the rituximab-containing treatment arm. These preliminary findings in a pilot study echo the results of previously published studies in advanced disease and provide a lead for future comparative trials. Although the majority of patients with limited disease can be cured using a brief course of doxorubicincontain...
متن کاملMantle Cell Lymphoma.
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of maintenance rituximab and bendamustine in older ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports in Hematology
سال: 2014
ISSN: 2090-6560,2090-6579
DOI: 10.1155/2014/621017